However, other notable trends were SLCO2B1 decreased expression by stage in pancreatic cancer, SLCO1B3 increased frequency by stage in prostate cancer, and SLCO1B1 decreased expression by stage in liver cancer. Here, SLCO2B1 is linked to prostate carcinoma.